Digest Network Come funziona
Network
/
Società
No
Non verificato

Novartis Pharma AG

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

106 comunicati stampa

Guarda tutti i comunicati
12/06/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
10/06/2026
Farmaceutica
Annunci Economici
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
08/06/2026
Farmaceutica
Annunci Economici
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
04/06/2026
Farmaceutica
Annunci Economici
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
03/06/2026
Farmaceutica
Annunci Economici
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
01/06/2026
Farmaceutica
Annunci Economici
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
31/05/2026
Farmaceutica
Annunci Economici
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
30/05/2026
Farmaceutica
Annunci Economici
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
25/05/2026
Farmaceutica
Annunci Economici
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
20/05/2026
Farmaceutica
Annunci Economici
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0